Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing and cell therapies, has appointed Dr. Adrian Kilcoyne as its new Chief Medical Officer. Dr. Kilcoyne brings extensive experience in oncology and cell therapy from his previous roles at Celularity, Humanigen, AstraZeneca, and Celgene. His appointment is expected to strengthen Cellectis' clinical development efforts in advancing their pipeline of next-generation CAR T-cell therapies.
Dr. Kilcoyne's background includes a medical degree from Trinity College, Dublin, training in Gynecological Oncology and Public Health Medicine, and an MBA. He replaces Dr. Mark Frattini, who is departing to pursue other opportunities. The company's CEO, André Choulika, expressed confidence in Dr. Kilcoyne's ability to contribute to Cellectis' mission of providing transformative UCART therapies to patients with significant unmet medical needs.
Cellectis (NASDAQ: CLLS), un azienda biotecnologica in fase clinica focalizzata su editing genetico e terapie cellulari, ha nominato Dr. Adrian Kilcoyne come nuovo Chief Medical Officer. Il Dr. Kilcoyne porta un'ampia esperienza in oncologia e terapia cellulare dai suoi precedenti ruoli in Celularity, Humanigen, AstraZeneca e Celgene. Ci si aspetta che la sua nomina rafforzi gli sforzi di sviluppo clinico di Cellectis per far avanzare il loro pipeline di terapie CAR T-cell di nuova generazione.
Il background del Dr. Kilcoyne include una laurea in medicina dal Trinity College di Dublino, formazione in Oncologia Ginecologica e Medicina della Salute Pubblica, e un MBA. Sostituisce il Dr. Mark Frattini, che lascia per intraprendere altre opportunità. L'amministratore delegato dell'azienda, André Choulika, ha espresso fiducia nella capacità del Dr. Kilcoyne di contribuire alla missione di Cellectis di fornire terapie UCART trasformative ai pazienti con significativi bisogni medici insoddisfatti.
Cellectis (NASDAQ: CLLS), una empresa biotecnológica en etapa clínica centrada en edición genética y terapias celulares, ha nombrado a Dr. Adrian Kilcoyne como su nuevo Director Médico. El Dr. Kilcoyne aporta una amplia experiencia en oncología y terapia celular de sus roles anteriores en Celularity, Humanigen, AstraZeneca y Celgene. Se espera que su nombramiento refuerce los esfuerzos de desarrollo clínico de Cellectis para avanzar en su cartera de terapias CAR T-cell de próxima generación.
El historial del Dr. Kilcoyne incluye un título de médico del Trinity College de Dublín, formación en Oncología Ginecológica y Medicina de Salud Pública, y un MBA. Reemplaza al Dr. Mark Frattini, quien se marcha para seguir otras oportunidades. El CEO de la empresa, André Choulika, expresó confianza en la capacidad del Dr. Kilcoyne para contribuir a la misión de Cellectis de proporcionar terapias UCART transformadoras a pacientes con importantes necesidades médicas no atendidas.
Cellectis(NASDAQ: CLLS)는 유전자 편집 및 세포 치료에 집중하는 임상 단계의 생명공학 회사로, Dr. Adrian Kilcoyne를 새로운 최고 의료 책임자로 임명했습니다. Kilcoyne 박사는 Celularity, Humanigen, AstraZeneca 및 Celgene에서의 이전 역할을 통해 종양학 및 세포 치료에 대한 광범위한 경험을 제공합니다. 그의 임명은 Cellectis의 차세대 CAR T-cell 치료 파이프라인 개발 노력을 강화할 것으로 예상됩니다.
Kilcoyne 박사의 배경은 더블린의 트리니티 대학교에서 의학 학위를 취득하고, 여성 종양학 및 공공 건강 의학에서 훈련을 받았으며, MBA를 보유하고 있습니다. 그는 다른 기회를 추구하기 위해 떠나는 Dr. Mark Frattini를 대신합니다. 회사의 CEO인 André Choulika는 Kilcoyne 박사가 중요한 의료적 요구를 충족시키기 위한 Cellectis의 변혁적인 UCART 치료를 제공하는 임무에 기여할 수 있을 것이라고 확신한다고 밝혔습니다.
Cellectis (NASDAQ: CLLS), une entreprise biopharmaceutique en phase clinique axée sur l'édition génétique et les thérapies cellulaires, a nommé Dr. Adrian Kilcoyne comme nouveau Directeur Médical. Le Dr Kilcoyne apporte une vaste expérience en oncologie et thérapie cellulaire de ses précédents postes chez Celularity, Humanigen, AstraZeneca et Celgene. Son nomination est censée renforcer les efforts de développement clinique de Cellectis pour faire avancer leur pipeline de thérapies CAR T-cell de nouvelle génération.
Le parcours du Dr Kilcoyne comprend un diplôme de médecine du Trinity College de Dublin, une formation en oncologie gynécologique et médecine de santé publique, ainsi qu'un MBA. Il remplace le Dr Mark Frattini, qui part pour poursuivre d'autres opportunités. Le PDG de l'entreprise, André Choulika, a exprimé sa confiance en la capacité du Dr Kilcoyne à contribuer à la mission de Cellectis de fournir des thérapies UCART transformantes aux patients ayant des besoins médicaux non satisfaits significatifs.
Cellectis (NASDAQ: CLLS), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf Genbearbeitung und zelluläre Therapien konzentriert, hat Dr. Adrian Kilcoyne als neuen Chief Medical Officer ernannt. Dr. Kilcoyne bringt umfassende Erfahrung in Onkologie und zellulärer Therapie aus seinen früheren Positionen bei Celularity, Humanigen, AstraZeneca und Celgene mit. Seiner Ernennung wird erwartet, dass sie die klinischen Entwicklungsbemühungen von Cellectis zur Weiterentwicklung ihrer next-generation CAR-T-Zelltherapien verstärkt.
Dr. Kilcoynes Werdegang umfasst einen medizinischen Abschluss vom Trinity College in Dublin, eine Ausbildung in gynäkologischer Onkologie und öffentlicher Gesundheitsmedizin sowie einen MBA. Er ersetzt Dr. Mark Frattini, der das Unternehmen verlässt, um andere Möglichkeiten zu verfolgen. Der CEO des Unternehmens, André Choulika, äußerte Vertrauen in die Fähigkeit von Dr. Kilcoyne, zur Mission von Cellectis beizutragen, transformative UCART-Therapien für Patienten mit erheblichen unbeantworteten medizinischen Bedürfnissen bereitzustellen.
- Appointment of Dr. Adrian Kilcoyne as Chief Medical Officer, bringing extensive experience in oncology and cell therapy
- Dr. Kilcoyne's background includes leadership roles at major pharmaceutical and biotechnology companies
- The new CMO's experience is expected to strengthen Cellectis' clinical development efforts
- Departure of previous Chief Medical Officer, Dr. Mark Frattini
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Dr. Adrian Kilcoyne, M.D., MPH, MBA as its Chief Medical Officer, effective immediately.
“We’re thrilled to welcome Dr. Kilcoyne to Cellectis. He is a strategic, forward-thinking drug developer who is passionate about delivering life-saving therapies to patients. His clinical vision and proven leadership, as well as his extensive experience, will strengthen our clinical development efforts as we advance our product pipeline of next-generation CAR T-cell therapies,” said André Choulika, Ph.D., Chief Executive Officer at Cellectis.
Before joining Cellectis, Dr. Kilcoyne was Chief Medical Officer and Head of Research and Development at Celularity, advancing their oncology allogeneic CAR-T and NK Cell therapy programs. Prior to this, he was Chief Medical Officer at Humanigen. He has held numerous Oncology leadership roles across Research and Development, Medical Affairs, Commercial, Health Economic Outcome Research and Evidence Generation in both large pharmaceutical and biotechnology companies such as AstraZeneca and Celgene. Dr. Kilcoyne graduated from Trinity College, Dublin Medical School. He initially trained in Gynecological Oncology at the Hammersmith Hospital in London and subsequently in Public Health Medicine at Oxford during which time he completed a Master’s in Public Health. Dr. Kilcoyne then trained in pharmaceutical medicine and completed his MBA.
“I am excited to join Cellectis at this pivotal time for the company as it is poised to deliver on its mission to provide transformative UCART therapies to patients with significant unmet medical need,” said Dr. Adrian Kilcoyne. “I believe that Cellectis’ world-class capabilities in gene editing and cell therapy manufacturing, promising pipeline and experienced leadership team will enable us to accelerate our current clinical pipeline and drive future innovation as we strive to deliver first-in-class and best-in-class allogeneic cell and gene therapies.”
Dr. Mark Frattini departs Cellectis effective immediately to pursue other opportunities. We thank Dr. Frattini for his contributions and wish him well in his new endeavors.
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 24 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
Forward-looking Statements
This press release contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “believe,” “poised to”, and “will,” or the negative of these and similar expressions. These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management. Forward-looking statements include statements about the advancement of development of our product candidates' pipeline, and the potential of our product candidate. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development. With respect to our cash runway, our operating plans, including product development plans, may change as a result of various factors, including factors currently unknown to us. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2023 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980, investors@cellectis.com
Attachment
FAQ
Who is the new Chief Medical Officer of Cellectis (CLLS)?
What is Dr. Adrian Kilcoyne's background before joining Cellectis (CLLS)?
What type of therapies is Cellectis (CLLS) developing?
Why did Cellectis (CLLS) appoint a new Chief Medical Officer?
